Patients with luminal breast cancers that are hormone receptor positive (estrogen receptor (ER+) and progesterone receptor (PR+)), may suffer cancer recurrence, which often metastasize to bone but respond well to endocrine therapies [2, 3]. This evidence concerns the gene ESR1 and breast cancer.